



BRIGHAM AND  
WOMEN'S HOSPITAL

| Heart & Vascular Center |

Going to ESC Congress 2017? For the latest in research and clinical advances, be sure to attend the many debates, lectures and poster presentations by Brigham and Women's Hospital cardiovascular specialists in Barcelona, August 26<sup>th</sup> to August 30<sup>th</sup>, 2017.

---

## Notable BWH Presentations

---

### Sunday, August 27<sup>th</sup>

- 11:00AM-12:30PM  
**Dr. Peter Libby**  
Lipids in Atherosclerosis – Evolving Concepts Co-Chair  
Location: Dublin – Village 1
  
- 11:15AM  
**Dr. Marc Sabatine**  
Do we need PCSK9 inhibitors in post-MI patients?  
Location: Dali – The Hub
  
- 11:55AM  
**Dr. Marc Sabatine**  
Do we need PCSK9 inhibitors in post-MI patients? Rebuttal PRO  
Location: Dali – The Hub
  
- 12:04PM  
**Dr. Eugene Braunwald**  
Discussant review: Cardiovascular Outcomes for People using Anticoagulation Strategies (COMPASS) trial: Primary Results  
Hot Line: Late-Breaking Clinical Trials 1  
Location: Barcelona – Main Auditorium

- 12:50PM  
**Dr. Marc Sabatine**  
CVD prevention and event reduction  
PCSK9 inhibitors: the next chapter in cardiovascular disease prevention  
Location: Barcelona – Main Auditorium
  
- 1:15PM  
**Dr. Robert Giugliano**  
Translating ENGAGE AF-TIMI 48 into clinical practice  
DS Satellite Symposium, “The changing landscape of oral anticoagulation for atrial fibrillation”  
Location: Oslo – Village 7
  
- 2:00-2:22PM  
**Dr. Peter Libby**  
The Role of Inflammation in Vascular Disease  
Innate Immunity and Acute Coronary Syndromes  
Location: Dublin – Village 1
  
- 2:00-3:30PM  
**Dr. Mandeep Mehra**  
Advanced heart failure: when drugs alone are not enough - Selection criteria for transplantation and destination therapy  
Location: Lisbon – Village 9
  
- 2:10-2:30PM  
**Dr. Robert Giugliano**  
Press Conference - Clinical Trial Update 1  
Clinical efficacy and safety of achieving very low LDL-C levels with the PCSK9 inhibitor Evolocumab in the FOURIER outcomes trial  
Location: TBA
  
- 3:07PM  
**Dr. Eugene Braunwald**  
Sharing of Clinical trial data  
Developments in cardiovascular translational research  
Location: Goya – The Hub
  
- 4:30PM  
**Dr. Marc Sabatine**  
CSK9 inhibitors and cardiovascular outcomes – Represented in New England Journal of Medicine by the FOURIER and SPIRE trials  
Highlights from the New England Journal of Medicine: editors’ choice  
Location: Dali – The Hub

## Monday, August 28<sup>th</sup>

- 8:30AM-12:30PM  
**Dr. Arman Qamar**  
Thrombosis & Atrial Fibrillation  
Efficacy & Safety of Edoxaban vs. Warfarin in Patients with Atrial Fibrillation & Hepatic Disease: Insights from the ENGAGE AF-TIMI 48 Trial  
Location: Posters – Poster Area
- 8:30AM  
**Dr. Tze-Fan Chao**  
The usefulness of the TIMI-AF score in the prediction of ischemic stroke and bleeding for Asian patients with atrial fibrillation  
Location: Posters – Poster Area
- 8:48AM  
**Dr. Marc Bonaca**  
Growth differentiation factor 15 and bleeding risk with ticagrelor in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54  
Antithrombotic strategies in coronary artery disease  
Location: Agora 1 – Agora
- 9:37-10:00AM  
**Dr. Laura Mauri**  
Starting, stopping, and everything in between: recent data concerning dual antiplatelet therapy in ACS  
How long is long enough? When to stop DAPT after an acute coronary syndrome?  
Location: Bucharest – Village 8
- 9:37AM  
**Dr. Marc Pfeffer**  
Heart Failure Patients Tend to Have More Than One Problem: how to manage co-morbidities  
Kidney dysfunction in heart failure: why worry?  
Location: Lisbon Village – 9
- 12:07PM  
**Dr. Marc Pfeffer**  
Heart failure with preserved ejection fraction - A clinical dilemma  
Treatment of HFpEF: drugs and devices on the horizon  
Location: Warsaw Village – 9

- 12:50-12:55PM  
**Dr. Peter Libby**  
ATHEROSCLEROSIS AND SECONDARY CARDIOVASCULAR DISEASE PREVENTION:  
INFLAMMATION AND LDL-CHOLESTEROL  
Atherosclerosis and the cardiovascular continuum CO-CHAIR & Speaker  
Location: Bucharest – Village 8
  
- 1:05PM  
**Dr. Marc Pfeffer**  
GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: A new  
treatment paradigm?  
Translating trials into practice – Clinical implications  
Location: Miro – The Hub
  
- 1:25PM  
**Dr. Christian Ruff**  
How can we appropriately treat multimorbid patients with AF?  
Protecting patients through responsible use of novel oral anticoagulants (NOACs) ... The right  
dose for the right patient for stroke prevention  
Location: Chisinau – Village 4
  
- 2:22-2:45PM  
**Dr. Peter Libby**  
MAKING AN IMPACT: OPTIMAL SECONDARY PREVENTION FOLLOWING ACUTE  
CORONARYSYNDROMES  
Targeting inflammation in patients after an acute coronary syndrome  
Location: Bucharest – Village 8
  
- 2:30PM  
**Dr. Robert Giugliano**  
Clinical Trial Update 1  
Clinical efficacy and safety of achieving very low LDL-C levels with the PCSK9 inhibitor  
Evolocumab in the FOURIER outcomes trial  
Clinical Trial Update 1  
Location: Dali – The Hub
  
- 3:07PM  
**Dr. Eugene Braunwald**  
Drug therapy of heart failure: what is next?  
Options and challenges for drug therapy of heart failure  
Location: Warsaw – Village 9

- 3:45-4:10PM  
**Dr. Christian Ruff**  
Opening remarks – Addressing the needs of the multi-morbid patients with AF  
Location: Gaudi – The Hub
- 3:45-4:15PM  
**Dr. Peter Libby**  
ATHEROSCLEROSIS, CARDIOVASCULAR RISK FACTORS AND SECONDARY PREVENTION: ARE WE MAKING PROGRESS?  
Location: Miro – The Hub

## Tuesday, August 29<sup>th</sup>

- 8:30AM  
**Dr. Martin Landray**  
Clinical effects of anacetrapib in people with established vascular disease: Results of the Randomized Evaluation of the effects of anacetrapib through lipid-modification  
Hot-Line: Late-Breaking Clinical Trials 4  
Location: Barcelona – Main Auditorium
- 8:30AM  
**Dr. Eugene Braunwald**  
Positioning of the topic – Why left main disease is different  
Left main is now a domain of interventional cardiology  
Location: Spotlight Stage
- 12:30PM  
**Dr. Eugene Braunwald**  
Aspirin for life – Chairperson conclusion  
Aspirin for life  
Location: Dali – The Hub
- 1:05PM  
**Dr. Marc Bonaca**  
Emerging science: recent evidence and science on the horizon  
State of the art lipid treatment in coronary patients in 2017  
Location: Beirut – Village 3
- 2:00-3:30PM  
**Dr. Mandeep Mehra**  
Innovative treatment strategies in advanced heart failure  
State of the Art: advanced heart failure - The rise of machines  
Location: Warsaw – Village 9

➤ 4:48PM

**Dr. Gregory Piazza**

Interventions in the pulmonary circulation

Echocardiographic improvement after short-duration, low-dose tPA regimens for ultrasound-facilitated, catheter-based fibrinolysis in submassive PE: OPTALYSE-PE

Location: Rabat – Village 7

➤ 4:54PM

**Dr. Jaris DeGroot**

Edoxaban versus warfarin in patients with atrial fibrillation in relation to stroke risk. A sub analysis of the ENGAGE AF – TIMI 48 study

Anticoagulation in atrial fibrillation

Location: Agora 2 – Agora